Emgality demonstrated robust efficacy for patients consistent with previous studies, although it did not achieve statistical superiority versus active comparator on the primary endpoint Emgality ...

Eli Lilly and Company LLY announced that the FDA has granted approval to its CGRP antibody, Emgality injection (300 mg) for the preventive treatment of episodic cluster headache in adult patients.